Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed Nawsher Alam has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigation of a 2021 Diarrheal Outbreak in a Coastal Sub-district of Bangladesh and Its Seasonal Pattern

    by Jahidur Rahman, Masum Billah, Mahbubur Rahman, Alden Henderson, Immamul Muntasir, Subrota Malakar, Dipankar Das, Nawsher Alam, Zakir Hossain Habib, Tahmina Shirin

    Objectives: Diarrhea is a major health problem in Barisal, a coastal division of southern Bangladesh. In April 2021 a diarrheal outbreak was notified from Barisal health authorities. An investigation team was deployed to describe demographic characteristics and seasonal patterns, identify risk factors of diarrhea in the district, and implement control measures. Methods: We analyzed seasonality using district health information system for the period 2018–2021 and conducted a matched case-control study in Bakerganj, the most affected sub-district. Cases were residents reporting ≥3 loose watery stools within 24 hours during 18 Apr 2021–1 May 2021. Controls were randomly selected from neighbors of a case without any diarrheal illness. Descriptive statistics were used to summarize demographic characteristics and seasonal trends, and multivariable conditional logistic regression was used to assess associations between potential risk factors and diarrheal illness. Results: A total of 1,027 diarrheal cases were identified during the outbreak in Bakerganj. Cases increased annually in March (pre-monsoon season) and declined from June (monsoon season). We enrolled 66 cases and 132 matched controls. Drinking untreated surface water (adjusted odds ratio [AOR] 11.6, 95% confidence interval [CI] 2.4–56.3), preparing overnight fermented rice (AOR 2.5, 95% CI 1.1–5.3), and performing ablution (AOR 2.4, 95% CI 1.0–5.9) were significant risk factors. Using surface water treated by aluminum potassium sulfate was protective (AOR 0.3, 95% CI 0.1–0.7). Among stool samples, 27% (20/75) tested positive for Vibrio cholerae by rapid diagnostic test and 29% (11/38) by culture; 5 of 8 surface water samples tested were positive. Public Health Recommendations: This outbreak occurred before the monsoon and was linked to untreated surface water for drinking and household activities. Public health authorities should implement preventive measures to ensure safe drinking water and distribute sufficient amounts of aluminum potassium sulfate to treat surface water before the annual surge.

  • Open Access

    Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh

    by Marjahan Akhtar, Md. Rashedul Islam, Zahid Hasan Khan, Afroza Akter, Imam Tauheed, Tasnuva Ahmed, Ishtiakul Islam Khan, Mohammad Ashraful Amin, Fatema Khaton, Farhana Khanam, et al.

    Background: The dynamics of humoral immune responses following primary and booster COVID-19 vaccinations are crucial to understand in order to optimize vaccination strategies. This study evaluates the magnitude and durability of SARS-CoV-2-specific IgG antibody responses across different vaccines in a large cohort of Bangladeshi adults. Methods: A total of 6300 adults from nine hospitals across eight divisions of Bangladesh were enrolled. Participants received two primary doses of either ChAdOx1 nCoV-19 (Covishield, Serum Institute of India, n = 2855), mRNA-1273 (Moderna, n = 578), BNT162b2 (Pfizer-BioNTech, n = 121), or Vero-cell-inactivated (Sinopharm, n = 2746) vaccines. Booster doses were administered at one-year intervals post-primary vaccination. SARS-CoV-2 spike receptor-binding domain (RBD)-specific IgG antibody responses were measured by ELISA using serum from vaccinees at multiple time points after two primary and two booster doses. Results: A total of 3745 individuals received booster 1 (third dose), with 59% receiving heterologous boosters (a different vaccine regimen than the primary doses). Only 5.5% (n = 347) of participants received a second booster one year after the first booster (among them, 99% received BNT162b2). Our results suggest that heterologous boosters with the mRNA vaccine induced higher IgG levels than homologous boosters for individuals who received primary vaccination with adenovirus vector-based ChAdOx1 nCoV-19 or a Vero-cell-inactivated vaccine. However, in those who initially received the mRNA-based vaccine, both homologous and heterologous boosters produced comparable IgG responses. Among all vaccine types, booster immunization with the Vero-cell-inactivated vaccine induced the lowest antibody responses. Longitudinal analysis demonstrated significantly high IgG levels over the 12 months following the first booster (p < 0.0001); however, IgG levels declined significantly after the second booster dose (fourth dose). Conclusions: Heterologous boosting strategies, particularly those involving mRNA vaccines, elicit stronger and more sustained IgG responses compared to a homologous booster. However, antibody waning after the second booster highlights the need for continued monitoring and potential additional vaccine strategies.

  • Open Access

    Factors Predicting the Outcome in Patients With Acute Encephalitis Syndrome: A Retrospective Analysis of Surveillance Data in Bangladesh

    by Dewan Imtiaz Rahman, Faruq Abdulla, Wasik Rahman Aquib, Md Mustafizur Rahman, Muhammad Rashedul Alam, Shadman Sakib Choudhury, Mohammad Rezaul Karim, Arifa Nazneen, Kamal Ibne Amin Chowdhury, Tonmoy Sarkar, et al.

    Introduction: Acute encephalitis syndrome (AES) is a severe inflammatory condition affecting the central nervous system, frequently leading to significant morbidity and mortality. Despite advancements in diagnostic techniques, the etiology of AES remains unidentified in a substantial number of cases, particularly in low‐ and middle‐income countries like Bangladesh. Understanding factors that predict outcomes in AES patients is crucial for improving management strategies and patient outcomes. Methods: We used data from the Nipah surveillance in Bangladesh, analyzing patients admitted with AES to 11 surveillance hospitals across diverse geographical regions in Bangladesh from January 2021 to December 2023. Trained surveillance team members screened patients and collected data through face‐to‐face interviews using a structured questionnaire, and surveillance physicians made decisions on enrollment as an AES case. Bivariate and multivariable logistic regression analyses were used to identify predictors of mortality. Results: A total of 12,603 AES patients were included, of whom 2,759 (22%) died. Mortality rates varied significantly across different administrative divisions, with the highest rates observed in the Rangpur division. Increased age, female sex, and delayed hospital admission were associated with higher odds of mortality. Patients from divisions like Rangpur and those aged 60 or over had notably higher odds of mortality, with adjusted odds ratios of 2.55 and 4.22, respectively. Clinical factors such as high pulse rate, ronchi, difficulty breathing, altered mental status, stiff neck, paralysis, and unconsciousness at admission were significantly associated with unfavorable outcomes. Discussion: The findings highlight significant geographical, demographic, and clinical predictors of mortality among AES patients in Bangladesh. Older age, delayed hospital admission, and certain reported clinical symptoms on admission increase the risk of death. The study underscores the importance of timely intervention and targeted management strategies, particularly in identified aforementioned high‐risk groups. Conclusion: Identifying predictors of adverse outcomes in AES patients can aid in developing early warning and triage systems, potentially enabling adequate resource allocation and the delivery of timely, personalized, and higher standard of care.

  • Open Access

    National Hospital-Based Sentinel Surveillance for Cholera in Bangladesh: Epidemiological Results from 2014 to 2021

    by Taufiqul Islam, Sonia Tara Hegde, Ashraful Islam Khan, Taufiqur Rahman Bhuiyan, Zahid Hasan Khan, Faisal Ahmmed, Yasmina Ara Begum, Mokibul Hassan Afrad, Mohammad Ashraful Amin, Nabid Anjum Tanvir, et al.

    : Despite focusing on cholera burden, epidemiologic studies in Bangladesh tend to be limited in geographic scope. National-level cholera surveillance data can help inform cholera control strategies and assess the effectiveness of preventive measures. Hospital-based sentinel surveillance among patients with suspected diarrhea in different sites across Bangladesh has been conducted since 2014. We selected an age-stratified sample of 20 suspected cholera cases each week from each sentinel site, tested stool for the presence of Vibrio cholerae O1/O139 by culture, and characterized antibiotic susceptibility in a subset of culture-positive isolates. We estimated the odds of being culture positive among suspected cholera cases according to different potential risk factors. From May 4, 2014 through November 30, 2021, we enrolled 51,414 suspected cases from our sentinel surveillance sites. We confirmed V. cholerae O1 in 5.2% of suspected cases through microbiological culture. The highest proportion of confirmed cholera cases was from Chittagong (9.7%) and the lowest was from Rangpur Division (0.9%). Age, number of purges, duration of diarrhea, occupation, and season were the most relevant factors in distinguishing cholera-positive suspected cases from cholera-negative suspected cases. Nationwide surveillance data show that cholera is circulating in Bangladesh and the southern region is more affected than the northern region. Antimicrobial resistance patterns indicate that multidrug resistance (resistance to three or more classes of antibiotics) of V. cholerae O1 could be a major threat in the future. Alignment of these results with Bangladesh’s cholera-control program will be the foundation for future research into the efficacy of cholera-control initiatives.


  • Open Access

    Measuring the Effectiveness of COVID-19 Vaccines Used during a Surge of the Delta Variant of SARS-CoV-2 in Bangladesh: A Test-Negative Design Evaluation

    by Farhana Khanam, Taufiqul Islam, Faisal Ahmmed, Shams Uddin Ahmed, Ismail Hossen, MdNazmul Hasan Rajib, Shahinur Haque, Prasanta Kumar Biswas, Imam Tauheed, K Zaman, et al.

    Background: From May to December 2021, Bangladesh experienced a major surge in the Delta variant of SARS-CoV-2. The earlier rollout of several vaccines offered the opportunity to evaluate vaccine effectiveness against this variant. Methods: A prospective, test-negative case-control study was conducted in five large hospitals in Dhaka between September and December 2021. The subjects were patients of at least 18 years of age who presented themselves for care, suffering COVID-like symptoms of less than 10 days’ duration. The cases had PCR-confirmed infections with SARS-CoV-2, and up to 4 PCR test-negative controls were matched to each case, according to hospital, date of presentation, and age. Vaccine protection was assessed as being the association between the receipt of a complete course of vaccine and the occurrence of SARS-CoV-2 disease, with symptoms beginning at least 14 days after the final vaccine dose. Results: In total, 313 cases were matched to 1196 controls. The genotyping of case isolates revealed 99.6% to be the Delta variant. Receipt of any vaccine was associated with 12% (95% CI: −21 to 37, p = 0.423) protection against all episodes of SARS-CoV-2. Among the three vaccines for which protection was evaluable (Moderna (mRNA-1273); Sinopharm (Vero Cell-Inactivated); Serum Institute of India (ChAdOx1 nCoV-19)), only the Moderna vaccine was associated with significant protection (64%; 95% CI: 10 to 86, p = 0.029). Protection by the receipt of any vaccine against severe disease was 85% (95% CI: 27 to 97, p = 0.019), with protection estimates of 75% to 100% for the three vaccines. Conclusions: Vaccine protection against COVID-19 disease of any severity caused by the Delta variant was modest in magnitude and significant for only one of the three evaluable vaccines. In contrast, protection against severe disease was high in magnitude and consistent for all three vaccines. Because our findings are not in complete accord with evaluations of the same vaccines in more affluent settings, our study underscores the need for country-level COVID-19 vaccine evaluations in developing countries.


  • Open Access

    Combining rapid antigen testing and syndromic surveillance improves community-based COVID-19 detection in a low-income country

    by Fergus J. Chadwick, Jessica Clark, Shayan Chowdhury, Tasnuva Chowdhury, David J. Pascall, Yacob Haddou, Joanna Andrecka, Mikolaj Kundegorski, Craig Wilkie, Eric Brum, et al.

    Diagnostics for COVID-19 detection are limited in many settings. Syndromic surveillance is often the only means to identify cases but lacks specificity. Rapid antigen testing is inexpensive and easy-to-deploy but can lack sensitivity. We examine how combining these approaches can improve surveillance for guiding interventions in low-income communities in Dhaka, Bangladesh. Rapid-antigen-testing with PCR validation was performed on 1172 symptomatically-identified individuals in their homes. Statistical models were fitted to predict PCR-status using rapid-antigen-test results, syndromic data, and their combination. Under contrasting epidemiological scenarios, the models’ predictive and classification performance was evaluated. Models combining rapid-antigen-testing and syndromic data yielded equal-to-better performance to rapid-antigen-test-only models across all scenarios with their best performance in the epidemic growth scenario. These results show that drawing on complementary strengths across rapid diagnostics, improves COVID-19 detection, and reduces false-positive and -negative diagnoses to match local requirements; improvements achievable without additional expense, or changes for patients or practitioners.


  • Open Access

    Antibody Responses after COVID-19 Infection in Patients Who Are Mildly Symptomatic or Asymptomatic in Bangladesh

    by Tahmina Shirin, Taufiqur R. Bhuiyan, Richelle C. Charles, Shaheena Amin, Imran Bhuiyan, Zannat Kawser, Asifuzaman Rahat, Ahmed Nawsher Alam, Sharmin Sultana, Abdul Aleem, et al.

    Studies on serologic responses following COVID-19 have been published primarily in individuals who are moderately or severely symptomatic, but there are few data from individuals who are only mildly symptomatic or asymptomatic. To generate such data, we used World Health Organization disease severity categorization, and measured IgG, IgM, and IgA antibodies to the receptor binding domain (RBD) of spike protein of SARS-CoV-2 by ELISA in infected individuals, both mildly symptomatic (n=108) and asymptomatic (n=63) on days 1, 7, 14, and 30 following RT-PCR-based confirmation of infection in Bangladesh, and compared these results to those detected in pre-pandemic samples, including healthy controls (n=73) and individuals infected with other viruses commonly seen in this area (n = 79). Mildly symptomatic individuals developed IgM and IgA antibody responses by day 14 after detection of infection in 72% and 83% of individuals, respectively, while 95% of these individuals developed an IgG antibody response by day 14, and rose to 100% by day 30. In contrast, individuals infected with SARS-CoV-2 but who remained asymptomatic developed antibody responses significantly less frequently, with only 20% positive for IgA by day 14, 22% positive for IgM by day 14, and 45% positive for IgG by day 30 after detection of infection. These results confirm that immune responses are generated following COVID in individuals who develop mildly symptomatic illness. However, those with asymptomatic infection do not respond or have lower antibody levels. These results will impact modelling needed for determining herd immunity generated by natural infection or vaccination. Funding Statement: World Health Organization, Fogarty International Center TW005572 and Emerging Global Leader Award; K43 TW010362, the Fondation Merieux and the Bill and Melinda Gates Foundation (BMGF). This study was carried out with the support of the United States Agency for International Development (USAID) under the terms of USAID’s Alliance for Combating TB in Bangladesh activity cooperative agreement no. CA # 72038820CA00002. Declaration of Interests: The authors declare no conflict of interest. Ethics Approval Statement: The study was also approved by the IRB of the IEDCR and icddr,b.